tiprankstipranks
Trending News
More News >
KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Japanese Market
Advertisement

KYORIN Pharmaceutical Co.,Ltd. (4569) Price & Analysis

Compare
3 Followers

4569 Stock Chart & Stats


KYORIN Pharmaceutical Co.,Ltd. News

4569 FAQ

What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1331.00 and its highest was ¥1698.00 in the past 12 months.
    What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
    KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥80.28B.
      When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
      KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Nov 06, 2025 which is in 68 days.
        How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
        KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Jul 31, 2025. The company reported ¥36.57 earnings per share for the quarter, beating the consensus estimate of N/A by ¥36.57.
          Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
          According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
            KYORIN Pharmaceutical Co.,Ltd. pays a Annually dividend of ¥20 which represents an annual dividend yield of 3.42%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
              What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
              KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
              KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
                What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
                KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥36.57 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
                  Currently, no hedge funds are holding shares in JP:4569

                  Company Description

                  KYORIN Pharmaceutical Co.,Ltd.

                  KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company primarily focuses on respiratory, otolaryngology, urology, and infectious diseases. Its core products include prescription medicines, over-the-counter drugs, and consumer healthcare products. KYORIN Pharmaceutical is committed to improving health and quality of life through innovative solutions and medical advancements.

                  KYORIN Pharmaceutical Co.,Ltd. (4569) Earnings & Revenues

                  4569 Stock 12 Month Forecast

                  Average Price Target

                  ¥1,706.00
                  ▲(12.68% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1337":"¥1,337","1522":"¥1,522","1707":"¥1,707","1429.5":"¥1,429.5","1614.5":"¥1,614.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥1.71K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥1.71K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.71K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1337,1429.5,1522,1614.5,1707],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1495,1511.2307692307693,1527.4615384615386,1543.6923076923076,1559.923076923077,1576.1538461538462,1592.3846153846155,1608.6153846153845,1624.8461538461538,1641.076923076923,1657.3076923076924,1673.5384615384614,1689.7692307692307,{"y":1706,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1495,1511.2307692307693,1527.4615384615386,1543.6923076923076,1559.923076923077,1576.1538461538462,1592.3846153846155,1608.6153846153845,1624.8461538461538,1641.076923076923,1657.3076923076924,1673.5384615384614,1689.7692307692307,{"y":1706,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1495,1511.2307692307693,1527.4615384615386,1543.6923076923076,1559.923076923077,1576.1538461538462,1592.3846153846155,1608.6153846153845,1624.8461538461538,1641.076923076923,1657.3076923076924,1673.5384615384614,1689.7692307692307,{"y":1706,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1625.58,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1556.16,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1470.87,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1482.59,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1437.66,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1469.89,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1437.66,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1338.04,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1498,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1475,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1475,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1498,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1495,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Kissei Pharmaceutical Co
                  Torii Pharmaceutical Co
                  Towa Pharmaceutical Co
                  Mochida Pharmaceutical Co., Ltd.
                  ASKA Pharmaceutical Holdings Co., Ltd.

                  Ownership Overview

                  6.73%89.72%
                  Insiders
                  6.73%
                  Mutual Funds
                  ― Other Institutional Investors
                  89.72% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis